|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
October 2006FeaturesCover Story The First Generation of Biodrug Management: To What Results?A few years into the biologic era, payers’ first attempts at managing costs have looked a lot like, well, traditional pharmacy-control methods. The pioneers point to modest savings, but the complexity of biologics, their administration, and lack of competition make a simple cost-saving formula elusive. Feature On Specialty Pharmaceuticals: Reflections of a Second-Year Medical StudentHigh cost and lack of evidence-based data for biologics used to treat rare diseases raise coverage questions for payers. Are clinical practice guidelines the answer? Regulatory Opening the Door to Follow-on Proteins?When the FDA approved the follow-on protein Omnitrope in May, it gave generic drug makers the wedge they were hoping for. With pressure building in Washington, did Omnitrope push the door open – or was it just an anomaly? Clinical Variety of Biotech Therapies, Uses Take Prominence Among ASCO PresentationsPresentations included treatments of various cancers, advances in stem cell therapy, and how gene variations affect drug action. Leading Edge Avian Flu and the Quest for ImmunityWith the very real threat of a bird flu pandemic — and no natural immunity among humans — antiviral drug developers, the federal government, and academic researchers are racing to find innovative vaccines and therapies that are effective and can be mass produced. The commercial payoff, too, could be big. DepartmentsOpeners Can You Put a Price on This?
Michael D. Dalzell Editorial ARO
David B. Nash, MD, MBA Washington Watch Global Stem Cell Industry Growing, But Can the U.S. Keep Up?
John Carroll Diagnostics and Devices BioCD, A Breakthrough Array Technology, Promises To Analyze More Proteins Faster And At A Lower Cost
Bob Carlson, MHA Drug Track Approvals, FDA Actions, Clinical Trials
Bob Carlson, MHA Corporate Spotlight Compliance With RSV Prophylaxis Can Reduce Hospitalizations Associated With RSV-Lower Respiratory Tract Infections In High-Risk Infants and Children
Frank J. Malinoski, MD, PhD Biotech Business Study: High Copayments Cut Biodrug Use up to 21 Percent
Amanda Brower Trends Big Pharma Moves Into Biologics |
|||||